European Psychiatry - Volume 41 - April 2017

546 / 916

S542 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S521–S582
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV0423
Clinical and neurocognitive
characteristics associated with
treatment-resistant depression
G. Serafini ∗ Adavastro Canepa onigliaro
M. Pompili , P. Girardi , M. Amore
1 University of Genoa, Neuroscience DINOGMI, Genoa, Italy
2 Suicide Prevention Center, Sant’ Andrea Hospital, Neurosciences,
Rome, Italy
3 Sant’Andrea Hospital, Neurosciences, Rome, Italy
∗ Corresponding author.
Introduction Treatment resistant depression (TRD) is a disabling
condition associated with a relevant psychosocial impairment
worldwide.
Objectives This exploratory study is aimed to evaluate the main
clinical and neurocognitive characteristics in a sample of 21 sub-
jects admitted to the Psychiatric Clinic of University of Genoa as
inpatients between 2015 and 2016 and diagnosedwith TRD accord-
ing to Thase and Rush staging method.
Methods Patients have been assessed using theHamiltonDepres-
sion Rating Scale (HDRS), Hamilton Anxiety Rating Scale, and
Clinical Global Impression (CGI). The Continuous Performance Test
(CPT), Trial Making Test (TMT-A/B), Stroop Color Word Interfer-
ence Test, Verbal Fluency Test, and Rey auditory-verbal learning
test (RAVLT) have been administered as well.
Results Subjects with early-onset (< 50 years) depression had
a longer illness duration, higher depressive episodes and more
impaired performance at RAVLT while individuals with late-onset
(> 50 years) depression showed a higher severity of depressive
symptoms and more anxiety symptoms. Depressive symptoms
were positively associated with anxiety (r = 0.82; P = 0.00) and
negatively with TMT-A/B (r = −0.56, P = 0.01), Stroop Color Word
Interference Test ( r = −0.72, P = 0.005 and r = −0.616, P = 0.008), and
RAVLT (r = −0.60; P = 0.02) performances. According to regression
analyses, anxiety symptoms were the only significant predictor of
depression severity (P= 0.02).
Conclusions Early-onset depression is associated with more dis-
ability and worse neurocognitive performance whereas late-onset
depression is linked to more anxiety symptoms and more depres-
sive symptoms severity. Clinicians should closely monitor patients
with TRD for the presence of anxiety symptoms that may represent
a significant risk factor of poorer long-term outcome.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV0424
Chronic benzodiazepine use in aged
patients with depressive disorder
N. Smaoui ouari Maâlej-Bouali Charfi ∗
N. Zouari en Thabet Maâlej
1 Hedi Chaker University Hospital, Department of Psychiatry- Hedi
Chaker University Hospital, Sfax, Tunisia
2 Hedi Chaker University Hospital, Department of Psychiatry C, Hedi
Chaker University Hospital, Sfax, Tunisia
∗ Corresponding author.
Objective To identify predictive variables of chronic benzodi-
azepine use among elderly patients with depressive disorder.
Methods This was a cross-sectional, descriptive and analytical
study, including 41 patients suffering from depressive disorders,
aged 65 years or more, treated with benzodiazepine (BZD) and
followed-up in outpatient psychiatry unit at Hedi Chaker university
hospital in Sfax in Tunisia. We used a standardized questionnaire
including socio-demographic and clinical data. Chronic BZD use
was defined as BZD availability at least 50% of the days between
day 181 and day 365 following initiation.
Results The average age of patients was 69.29 ± 5.7 years. The
sex ratio (M/F) was 0.5. The majority of them were married (78%),
unemployed (82.9%) and living in urban area (61%). They had at
most a primary degree (90.2%) and a low socioeconomic level
(63.4%). The average time of BZD consumption was 4 years and
5months.
The prevalence of chronic BZD use in our sample was 56.1%.
Duration of benzodiazepine use was greater than 1 year for all
chronic BZD users. The mean dose of Benzodiazepine (Lorazepam)
consumed was 3.87 ±2.8mg per day. Chronic BZD use was cor-
related with low socioeconomic level (86.3% vs 36.8%; P = 0.000),
psychiatric comorbidity (72.7% vs 26.3%; P = 0.004) and recent hos-
pitalization (59% vs 15.7%; P = 0.023).
Conclusion There is a high prevalence of chronic BZD use in our
study. For the 65 years and older patients with depressive disorder,
significant predictors of chronic BZD use were low socioeconomic
level, psychiatric comorbidity and recent hospitalization.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV0425
Views of relatives and friends about
the person who is having first episode
of depression
S. Srivastava
Psychiatry, Lucknow, India
Introduction Major depressive episode is having highest lifetime
prevalence almost about 18% of all psychiatric disorder. W.H.O has
ranked depression the 4th leading cause of disability worldwide
and projects that it will be 2nd leading cause of disability by 2020.
a number of consistent socio demographic correlates have also been
found across countries. Here I amgoing to give a glimpse of MDD i.e.
Depression excluding Bipolar Depression. Although It is the com-
monest psychiatric disorder, but attitude views about disease is
very unscientific and biased.
Objective Objective of this study was to know the views of rela-
tives and friends about Depression, and acceptance of scientific
view about depression.
Aims As various survey reports are projecting that Depression
will be the 2nd commonest cause of disability by 2020. So to cre-
ate an awareness about depression and its modalities of successful
treatments.
Method In this study, 96 patients were selected who had first
episode of MDD without any discrimination of male and female.
Their relatives and friendswere categorized by their socioeconomic
status. All of them were put on open questions regarding the dis-
ease.
Results Amongst them 10% were from upper socioeconomic sta-
tus, 68%were frommiddle socioeconomic status and 22%were from
lower socioeconomic status. Only 36% accepted depression as a dis-
ease, 45.8% suggested to change behavior and thought to get rid off
disease; 8.2%believed the disease is due to devils spirit; 20.1% had
no comments.
Conclusion After explaining the disease psycho and pharmaco-
pathology and showing the results of medicines 91.3% accepted it
as a disease entity, 4.2% still in favor of devils spirit and 4.5% had
no comments.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.